Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT00191295 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine
DRUG: Placebo

Sponsor

Eli Lilly and Company